Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IRAK4 | Q9NWZ3 | 6/20 | 0.42 |
| ▸ | KCNQ3 | O43525 | 4/20 | 0.39 |
| ▸ | KCNQ2 | O43526 | 4/20 | 0.39 |
| ▸ | HPGD | P15428 | 3/20 | 0.39 |
| ▸ | APOBEC3A | P31941 | 2/20 | 0.38 |
| ▸ | APOBEC3G | Q9HC16 | 1/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.38 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.38 |
| ▸ | GAA | P10253 | 1/20 | 0.37 |
| ▸ | ATM | Q13315 | 1/20 | 0.37 |
| ▸ | NPC1 | O15118 | 1/20 | 0.37 |
| ▸ | RAB9A | P51151 | 1/20 | 0.37 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.37 |
| ▸ | MEN1 | O00255 | 2/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5133264 | 0.87 | APOBEC3A (0.45) | KCNQ3KCNQ2HPGDAPOBEC3AAPOBEC3G | |
| SCHEMBL17460386 | 0.80 | IRAK4 (0.45) | IRAK4KCNQ3KCNQ2HPGDAPOBEC3A | |
| SCHEMBL4312241 | 0.77 | IRAK4 (0.45) | IRAK4HPGDAPOBEC3AAPOBEC3GALDH1A1 | |
| SCHEMBL29788579 | 0.77 | KCNQ3 (0.39) | IRAK4KCNQ3KCNQ2HPGDAPOBEC3A | |
| SCHEMBL17460370 | 0.73 | HPGD (0.44) | IRAK4HPGDAPOBEC3AALDH1A1L3MBTL1 | |
| Trifluoroacetic Acid SCHEMBL30194359 | 0.73 | PIK3CG (0.42) | — | |
| SCHEMBL23649073 | 0.72 | IRAK4 (0.44) | IRAK4HPGDAPOBEC3AALDH1A1L3MBTL1 | |
| SCHEMBL17460362 | 0.72 | IRAK4 (0.41) | IRAK4KCNQ3KCNQ2HPGDAPOBEC3A | |
| SCHEMBL17460390 | 0.70 | HPGD (0.42) | IRAK4KCNQ3KCNQ2HPGDAPOBEC3A | |
| SCHEMBL19554509 | 0.70 | IRAK4 (0.47) | IRAK4APOBEC3AAPOBEC3GMEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2024359-A1 | COMPOUNDS THAT ARE AGONISTS OF MUSCARINIC RECEPTORS AND THAT MAY BE EFFECTIVE IN TREATING PAIN, ALZHEIMER'S DECEASE AND/OR SCHIZOPHRENIA | AstraZeneca AB (SE) | 2009-02-18 | — | — | EP | claimed |
| WO-2007126362-A1 | COMPOUNDS THAT ARE AGONISTS OF MUSCARINIC RECEPTORS AND THAT MAY BE EFFECTIVE IN TREATING PAIN, ALZHEIMER'S DISEASE AND/OR SCHIZOPHRENIA | ASTRAZENECA AB (SE) | 2007-11-08 | — | — | WO | claimed |
| US-20210338653-A1 | N-[2-(1 -BENZYLPIPERIDIN-4-YL)ETHYL]-4-(PYRAZIN-2-YL)-PIPERAZINE-1 -CARBOXAMIDE DERIVATIVES AND RELATED COMPOUNDS AS MUSCARINIC RECEPTOR 4 (M4) ANTAGONISTS FOR TREATING NEUROLOGICAL DISEASES | NEUROCRINE BIOSCIENCES, INC. | 2021-11-04 | — | — | US | disclosed |
| US-11033539-B2 | Compounds of formulas (VII), (VIII), (IX), (XI), (XII), (XIII), and (XIV) as muscarinic receptor 4(M4) antagonists for treating neurological diseases | NEUROCRINE BIOSCIENCES, INC. (US) | 2021-06-15 | — | — | US | disclosed |
| US-10633369-B2 | Method of inhibiting DYRK1B | 4 SC AG (DE) | 2020-04-28 | — | — | US | disclosed |
| US-20180325887-A1 | N-[2-(1-BENZYLPIPERIDIN-4-YL)ETHYL]-4-(PYRAZIN-2-YL)-PIPERAZINE-1-CARBOXAMIDE DERIVATIVES AND RELATED COMPOUNDS AS MUSCARINIC RECEPTOR 4 (M4) ANTAGONISTS FOR TREATING NEUROLOGICAL DISEASES | NEUROCRINE BIOSCIENCES, INC. | 2018-11-15 | — | — | US | disclosed |
| US-20180201606-A1 | METHOD OF INHIBITING DYRK1B | 4 SC AG (DE) | 2018-07-19 | — | — | US | disclosed |
| US-9951050-B2 | Method of inhibiting DYRK1B | 4 SC AG (DE) | 2018-04-24 | — | — | US | disclosed |
| US-20140371251-A1 | METHOD OF INHIBITING DYRK1B | 4SC DISCOVERY GMBH (DE) | 2014-12-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11033539-B2 | Compounds of formulas (VII), (VIII), (IX), (XI), (XII), (XIII), and (XIV) as muscarinic receptor 4(M4) antagonists for treating neurological diseases | CHRM2, CHRM4, CHRM1 | IRAK4 609/4885KCNQ3 1357/4885KCNQ2 1323/4885 |
| US-10633369-B2 | Method of inhibiting DYRK1B | SMO, GLI1, GRK2 | IRAK4 1625/4885KCNQ3 3975/4885KCNQ2 3911/4885 |
| US-20180325887-A1 | N-[2-(1-BENZYLPIPERIDIN-4-YL)ETHYL]-4-(PYRAZIN-2-YL)-PIPERAZINE-1-CARBOXAMIDE DERIVATIVES AND RELATED COMPOUNDS AS MUSCARINIC RECEPTOR 4 (M4) ANTAGONISTS FOR TREATING NEUROLOGICAL DISEASES | CHRM1, CHRM2, CHRM4 | IRAK4 864/4885KCNQ3 2501/4885KCNQ2 2156/4885 |
| US-20210338653-A1 | N-[2-(1 -BENZYLPIPERIDIN-4-YL)ETHYL]-4-(PYRAZIN-2-YL)-PIPERAZINE-1 -CARBOXAMIDE DERIVATIVES AND RELATED COMPOUNDS AS MUSCARINIC RECEPTOR 4 (M4) ANTAGONISTS FOR TREATING NEUROLOGICAL DISEASES | CHRM2, CHRM1, CHRM4 | IRAK4 870/4885KCNQ3 2654/4885KCNQ2 2294/4885 |
| US-20180201606-A1 | METHOD OF INHIBITING DYRK1B | SMO, GLI1, GRK2 | IRAK4 1625/4885KCNQ3 3975/4885KCNQ2 3911/4885 |
| US-20140371251-A1 | METHOD OF INHIBITING DYRK1B | SMO, GLI1, GRK2 | IRAK4 1625/4885KCNQ3 3975/4885KCNQ2 3911/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.